Attached files

file filename
10-Q - FORM 10-Q - SALIX PHARMACEUTICALS LTDd10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex311.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex321.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - SALIX PHARMACEUTICALS LTDdex312.htm
EX-10.68 - RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT WITH LUPIN LTD. - SALIX PHARMACEUTICALS LTDdex1068.htm
EX-10.67 - DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT WITH LUPIN LTD. - SALIX PHARMACEUTICALS LTDdex1067.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended September 30, 2009 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Adam C. Derbyshire, Executive Vice President, Finance and Administration, and Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

 

  Date:  

            November 9, 2009            

    By:  

/s/ Adam C. Derbyshire

          Adam C. Derbyshire
          Executive Vice President and
          Chief Financial Officer